10 completed, 7 unknown, 4 recruiting, 1 enrolling by invitation. 8 Phase 3, 7 Phase 2, 3 Not applicable, 2 Phase 1, 2 Phase 4.
Follow Non-Proliferative Diabetic Retinopathy: new trials by email Literature Review of Non-Proliferative Diabetic Retinopathy trials Research Report on Non-Proliferative Diabetic Retinopathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24, Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24, Sham/mock procedure of intravitreal injection followed by a second sham/mock procedure at Week 24 - Non-Proliferative Diabetic Retinopathy | Phase 3 | Recruiting | Ocular Therapeutix, Inc. | 930 | 2025-11-17 | 2026-03-16 |
| Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Diabetic Retinopathy or Retinal Vein Occlusion ANXV - Non-Proliferative Diabetic Retinopathy, Retinal Vein Occlusion | Phase 2 | Recruiting | Annexin Pharmaceuticals AB | 12 | 2025-11-07 | 2025-12-02 |
| Clinical Study on the Efficacy and Safety of TNTL in the Treatment of Non-proliferative Diabetic Retinopathy TNTL, TNTL simulation preparation - Non-Proliferative Diabetic Retinopathy | Phase 3 | Recruiting | Beletalent (Zhuhai) Pharmaceutical Co., Ltd | 360 | 2025-04-29 | 2025-08-24 |
| Remote Ischemic Conditioning for Non-Proliferative Diabetic Retinopathy Remote Ischemic Conditioning Device, Sham Remote Ischemic Conditioning Device - Diabetic Retinopathy, Non-Proliferative Diabetic Retinopathy | Not applicable | Recruiting | Xuxiang Zhang, MD | 68 | 2025-04-20 | 2025-06-26 |
| A Study to Learn How Safe BAY3283142 is When Taken as a Single Dose or as Multiple Doses in Healthy Chinese Participants BAY3283142, Placebo - Chronic Kidney Disease, Non-proliferative Diabetic Retinopathy | Phase 1 | Completed | Bayer | 24 | 2024-07-04 | 2024-09-24 |
| Safety and Efficacy of Faricimab in Patients With NPDR Faricimab - Non-Proliferative Diabetic Retinopathy | Phase 2 | Completed | Greater Houston Retina Research | 179 | 2023-05-16 | 2026-03-20 |
| Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy OTX-TKI, Sham - Non-proliferative Diabetic Retinopathy | Phase 1 | Unknown | Ocular Therapeutix, Inc. | 21 | 2023-01-15 | 2023-12-08 |
| Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy OPL-0401 Dose 1, Placebo - Non-proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy | Phase 2 | Unknown | Valo Health, Inc. | 114 | 2022-08-16 | 2024-06-17 |
| To Evaluate the Efficacy and Safety of Combination Therapy With B55R1 and B55R2 Compared to B55R1 Monotherapy in Patients With NPDR B55R1 and B55R2, B55R1 and placebo for B55R2 - Non-Proliferative Diabetic Retinopathy | Phase 4 | Completed | AJU Pharm Co., Ltd. | 53 | 2022-04-28 | 2026-09-04 |
| Intravitreal and Intracameral DEX in NPDR Dexamethasone sodium phosphate - Non-Proliferative Diabetic Retinopathy | Phase 3 | Enrolling by invitation | Affiliated Hospital of Nantong University | 80 | 2022-01-31 | 2025-04-30 |
| Anti-VEGF in Real-world Ranibizumab, Aflibercept, Conbercept - Neovascular Age-related Macular Edema, Diabetic Macular Edema | Unknown | Wenbin Wei | 1000 | 2022-01-01 | 2022-02-03 | |
| A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR) KSI-301, Sham injection - Non-proliferative Diabetic Retinopathy | Phase 3 | Terminated | Kodiak Sciences Inc | 253 | 2021-09-07 | 2024-09-05 |
| Intravitreal Bevacizumab for Nonproliferative Diabetic Retinopathy Intravitreal Bevacizumab IVB, Follow-up with regular examination for determination of DR progression - Non-proliferative Diabetic Retinopathy | Phase 2 / Phase 3 | Unknown | Shahid Beheshti University of Medical Sciences | 100 | 2020-09-01 | 2020-08-13 |
| The Effect of Combination of Vitamin A, Vitamin E, Sodium Hyaluronate 0.15% Eye Drop Compared With Sodium Hyaluronate 0.1% Eye Drop to Tear Film Stability and Conjunctival Goblet Cells Density in Patient With Non-Proliferative Diabetic Retinopathy (NPDR), and Proliferative Diabetic Retinopathy (PDR) Sodium Hyaluronate, Vitamin A, Vitamin E - Non-Proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy New Vessels on Disc | Not applicable | Unknown | Dr Cipto Mangunkusumo General Hospital | 96 | 2019-07-01 | 2019-06-27 |
| A Clinical Trial Designed to Evaluate the Safety and Efficacy Study of Luminate® in Inducing PVD (Posterior Vitreous Detachment) in Non-Proliferative Diabetic Retinopathy 1.0mg Luminate®, 2.0mg Luminate®, 3.0mg Luminate® - Non-Proliferative Diabetic Retinopathy | Phase 2 | Completed | Allegro Ophthalmics, LLC | 105 | 2015-02-01 | 2017-12-15 |
| Nepafenac Once Daily for Macular Edema - Study 1 Nepafenac Ophthalmic Suspension, 0.3%, Nepafenac vehicle, Prednisolone acetate - Non-Proliferative Diabetic Retinopathy, Cataract | Phase 3 | Completed | Alcon Research | 881 | 2013-06-01 | 2016-08-03 |
| Nepafenac Once Daily for Macular Edema - Study 2 Nepafenac Ophthalmic Suspension, 0.3%, Vehicle, Prednisolone acetate - Non-Proliferative Diabetic Retinopathy, Cataract | Phase 3 | Completed | Alcon Research | 819 | 2013-06-01 | 2016-08-02 |
| Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema Bevacizumab - Non-proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy | Phase 4 | Completed | King Khaled Eye Specialist Hospital | 50 | 2013-06-01 | 2021-12-03 |
| Phase III Study of Compound Danshen Dripping Pills to Treat Diabetic Retinopathy Compound danshen dripping pills, Placebo - Non-proliferative Diabetic Retinopathy | Phase 3 | Unknown | Tasly Pharmaceuticals, Inc. | 480 | 2013-05-01 | 2017-03-21 |
| Diabetes Visual Function Supplement Study multi-component nutritional supplement capsules, multi-component dietary supplement - Diabetes Mellitus - Type 1, Diabetes Mellitus - Type 2 | Not applicable | Completed | ZeaVision, LLC | 70 | 2012-05-01 | 2015-01-22 |
Showing 20 of 23. Sign in to see all of them.
Diabetes Mellitus, Type 2 (6) · Diabetic Retinopathy (5) · Macular Edema (4) · Diabetes Mellitus, Type 1 (3) · Cataract (2) · Diabetes Mellitus (2) · Retinal Vein Occlusion (2) · Dry Eye Syndromes (1) · Eye Diseases (1) · Mitochondrial Diseases (1) · Renal Insufficiency, Chronic (1) · Retinal Degeneration (1) · Retinal Diseases (1) · Vision Disorders (1)
Eye Diseases (11) · Retinal Diseases (10) · Endocrine System Diseases (9) · Cardiovascular Diseases (7) · Diabetes Mellitus (7) · Glucose Metabolism Disorders (7) · Metabolic Diseases (7) · Nutritional and Metabolic Diseases (7) · Vascular Diseases (7) · Diabetes Complications (5) · Diabetic Angiopathies (5) · Macular Degeneration (4) · Retinal Degeneration (4) · Autoimmune Diseases (3) · Immune System Diseases (3)
salicylhydroxamic acid (3) · Bevacizumab (2) · Methylprednisolone (2) · Vitamin E (2) · nepafenac (2) · prednisolone acetate (2) · Ascorbic Acid (1) · Calcium Dobesilate (1) · Copper (1) · Dexamethasone (1) · Hyaluronic Acid (1) · Intravitreal Injections (1) · KH902 fusion protein (1) · Lutein (1) · Ranibizumab (1)
Alcon Research (2) · Ocular Therapeutix, Inc. (2) · AJU Pharm Co., Ltd. (1) · Affiliated Hospital of Nantong University (1) · Allegro Ophthalmics, LLC (1) · Annexin Pharmaceuticals AB (1) · Bayer (1) · Beletalent (Zhuhai) Pharmaceutical Co., Ltd (1) · Dr Cipto Mangunkusumo General Hospital (1) · Greater Houston Retina Research (1) · King Khaled Eye Specialist Hospital (1) · Kodiak Sciences Inc (1) · Retina Macula Institute (1) · Shahid Beheshti University of Medical Sciences (1) · Soroka University Medical Center (1)
United States (8) · China (6) · Czechia (1) · Israel (1) · Latvia (1) · Mexico (1) · Poland (1) · Puerto Rico (1) · Saudi Arabia (1) · Slovakia (1) · South Korea (1) · Spain (1) · United Kingdom (1)
Adolfo D. Rodriguez-Carrizalez, M.Sc. (1) · Alan P. Chous, O.D. (1) · Allen Hu, MD (1) · Daniel Janer, MD (1) · Hadar Shalev, M.D (1) · Hongsheng Bi (1) · Min Zhao, PhD (1) · Pablo Velazquez-Martin, MD (1) · Ron P Gallemore, M.D, Ph.D (1) · Saba al Rashaed, MD (1) · Vicken Karageozian, MD (1)
PMID 22595020, PMID 26089210, PMID 32990945, PMID 41587134, PMID 41803826